Cargando…

LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro

AIMS/HYPOTHESIS: Activation of inflammatory pathways is involved in the pathogenesis of type 2 diabetes mellitus. On the basis of its role in vascular inflammation and in metabolic disorders, we hypothesised that the TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) could be involved in the pathogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Halvorsen, Bente, Santilli, Francesca, Scholz, Hanne, Sahraoui, Afaf, Gulseth, Hanne L., Wium, Cecilie, Lattanzio, Stefano, Formoso, Gloria, Di Fulvio, Patrizia, Otterdal, Kari, Retterstøl, Kjetil, Holven, Kirsten B., Gregersen, Ida, Stavik, Benedicte, Bjerkeli, Vigdis, Michelsen, Annika E., Ueland, Thor, Liani, Rossella, Davi, Giovanni, Aukrust, Pål
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016561/
https://www.ncbi.nlm.nih.gov/pubmed/27421726
http://dx.doi.org/10.1007/s00125-016-4036-y
_version_ 1782452582251233280
author Halvorsen, Bente
Santilli, Francesca
Scholz, Hanne
Sahraoui, Afaf
Gulseth, Hanne L.
Wium, Cecilie
Lattanzio, Stefano
Formoso, Gloria
Di Fulvio, Patrizia
Otterdal, Kari
Retterstøl, Kjetil
Holven, Kirsten B.
Gregersen, Ida
Stavik, Benedicte
Bjerkeli, Vigdis
Michelsen, Annika E.
Ueland, Thor
Liani, Rossella
Davi, Giovanni
Aukrust, Pål
author_facet Halvorsen, Bente
Santilli, Francesca
Scholz, Hanne
Sahraoui, Afaf
Gulseth, Hanne L.
Wium, Cecilie
Lattanzio, Stefano
Formoso, Gloria
Di Fulvio, Patrizia
Otterdal, Kari
Retterstøl, Kjetil
Holven, Kirsten B.
Gregersen, Ida
Stavik, Benedicte
Bjerkeli, Vigdis
Michelsen, Annika E.
Ueland, Thor
Liani, Rossella
Davi, Giovanni
Aukrust, Pål
author_sort Halvorsen, Bente
collection PubMed
description AIMS/HYPOTHESIS: Activation of inflammatory pathways is involved in the pathogenesis of type 2 diabetes mellitus. On the basis of its role in vascular inflammation and in metabolic disorders, we hypothesised that the TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) could be involved in the pathogenesis of type 2 diabetes mellitus. METHODS: Plasma levels of LIGHT were measured in two cohorts of type 2 diabetes mellitus patients (191 Italian and 40 Norwegian). Human pancreatic islet cells and arterial endothelial cells were used to explore regulation and relevant effects of LIGHT in vitro. RESULTS: Our major findings were: (1) in both diabetic cohorts, plasma levels of LIGHT were significantly raised compared with sex- and age-matched healthy controls (n = 32); (2) enhanced release from activated platelets seems to be an important contributor to the raised LIGHT levels in type 2 diabetes mellitus; (3) in human pancreatic islet cells, inflammatory cytokines increased the release of LIGHT and upregulated mRNA and protein levels of the LIGHT receptors lymphotoxin β receptor (LTβR) and TNF receptor superfamily member 14 (HVEM/TNFRSF14); (4) in these cells, LIGHT attenuated the insulin release in response to high glucose at least partly via pro-apoptotic effects; and (5) in human arterial endothelial cells, glucose boosted inflammatory response to LIGHT, accompanied by an upregulation of mRNA levels of HVEM (also known as TNFRSF14) and LTβR (also known as LTBR). CONCLUSIONS/INTERPRETATION: Our findings show that patients with type 2 diabetes mellitus are characterised by increased plasma LIGHT levels. Our in vitro findings suggest that LIGHT may contribute to the progression of type 2 diabetes mellitus by attenuating insulin secretion in pancreatic islet cells and by contributing to vascular inflammation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-016-4036-y) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-5016561
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-50165612016-09-19 LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro Halvorsen, Bente Santilli, Francesca Scholz, Hanne Sahraoui, Afaf Gulseth, Hanne L. Wium, Cecilie Lattanzio, Stefano Formoso, Gloria Di Fulvio, Patrizia Otterdal, Kari Retterstøl, Kjetil Holven, Kirsten B. Gregersen, Ida Stavik, Benedicte Bjerkeli, Vigdis Michelsen, Annika E. Ueland, Thor Liani, Rossella Davi, Giovanni Aukrust, Pål Diabetologia Article AIMS/HYPOTHESIS: Activation of inflammatory pathways is involved in the pathogenesis of type 2 diabetes mellitus. On the basis of its role in vascular inflammation and in metabolic disorders, we hypothesised that the TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) could be involved in the pathogenesis of type 2 diabetes mellitus. METHODS: Plasma levels of LIGHT were measured in two cohorts of type 2 diabetes mellitus patients (191 Italian and 40 Norwegian). Human pancreatic islet cells and arterial endothelial cells were used to explore regulation and relevant effects of LIGHT in vitro. RESULTS: Our major findings were: (1) in both diabetic cohorts, plasma levels of LIGHT were significantly raised compared with sex- and age-matched healthy controls (n = 32); (2) enhanced release from activated platelets seems to be an important contributor to the raised LIGHT levels in type 2 diabetes mellitus; (3) in human pancreatic islet cells, inflammatory cytokines increased the release of LIGHT and upregulated mRNA and protein levels of the LIGHT receptors lymphotoxin β receptor (LTβR) and TNF receptor superfamily member 14 (HVEM/TNFRSF14); (4) in these cells, LIGHT attenuated the insulin release in response to high glucose at least partly via pro-apoptotic effects; and (5) in human arterial endothelial cells, glucose boosted inflammatory response to LIGHT, accompanied by an upregulation of mRNA levels of HVEM (also known as TNFRSF14) and LTβR (also known as LTBR). CONCLUSIONS/INTERPRETATION: Our findings show that patients with type 2 diabetes mellitus are characterised by increased plasma LIGHT levels. Our in vitro findings suggest that LIGHT may contribute to the progression of type 2 diabetes mellitus by attenuating insulin secretion in pancreatic islet cells and by contributing to vascular inflammation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-016-4036-y) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2016-07-15 2016 /pmc/articles/PMC5016561/ /pubmed/27421726 http://dx.doi.org/10.1007/s00125-016-4036-y Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Halvorsen, Bente
Santilli, Francesca
Scholz, Hanne
Sahraoui, Afaf
Gulseth, Hanne L.
Wium, Cecilie
Lattanzio, Stefano
Formoso, Gloria
Di Fulvio, Patrizia
Otterdal, Kari
Retterstøl, Kjetil
Holven, Kirsten B.
Gregersen, Ida
Stavik, Benedicte
Bjerkeli, Vigdis
Michelsen, Annika E.
Ueland, Thor
Liani, Rossella
Davi, Giovanni
Aukrust, Pål
LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
title LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
title_full LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
title_fullStr LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
title_full_unstemmed LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
title_short LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
title_sort light/tnfsf14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016561/
https://www.ncbi.nlm.nih.gov/pubmed/27421726
http://dx.doi.org/10.1007/s00125-016-4036-y
work_keys_str_mv AT halvorsenbente lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT santillifrancesca lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT scholzhanne lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT sahraouiafaf lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT gulsethhannel lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT wiumcecilie lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT lattanziostefano lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT formosogloria lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT difulviopatrizia lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT otterdalkari lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT retterstølkjetil lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT holvenkirstenb lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT gregersenida lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT stavikbenedicte lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT bjerkelivigdis lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT michelsenannikae lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT uelandthor lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT lianirossella lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT davigiovanni lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro
AT aukrustpal lighttnfsf14isincreasedinpatientswithtype2diabetesmellitusandpromotesisletcelldysfunctionandendothelialcellinflammationinvitro